...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical drug investigation >Wegener's granulomatosis after treatment with montelukast in a patient not receiving systemic corticosteroid treatment
【24h】

Wegener's granulomatosis after treatment with montelukast in a patient not receiving systemic corticosteroid treatment

机译：未接受全身性皮质类固醇治疗的患者接受孟鲁司特治疗后韦格纳肉芽肿

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Leukotriene antagonists are the first new class of drugs for the treatment of asthma in more than 20 years. These drugs include one enzyme inhibitor of 5-lipoxygenase (zileuton) and three chemically dis tinct cysteinyl leukotriene type-1 receptor antagon ists(zafirlukast, pranlukast and montelukast). The greatest concern raised during treatment with cys teinyl leukotriene receptor antagonists is the development of Churg-Strauss syndrome (CSS). The causal role of these drugs in the development of CSS has not been completely clarified. It has been postulated that the induction of CSS is not due to direct effects of leukotriene antagonists, but rather indicates the emergence of an underlying disease because of the withdrawal of corticosteroids.
机译：白三烯拮抗剂是20多年来治疗哮喘的第一类新型药物。这些药物包括一种5-脂氧合酶的酶抑制剂（齐留通）和三种化学上不同的半胱氨酰白三烯1型受体拮抗剂（扎鲁司特，普鲁司特和孟鲁司特）。 cys teinyl leukotriene受体拮抗剂治疗期间引起的最大关注是Churg-Strauss综合征（CSS）的发展。这些药物在CSS发展中的因果作用尚未完全阐明。据推测，CSS的诱导不是由于白三烯拮抗剂的直接作用，而是表明由于皮质类固醇的戒断而导致潜在疾病的出现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号